116 related articles for article (PubMed ID: 38085056)
1. Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations.
Dabkowski TR; Varkhedi M; Song JJ; Gozlan EC; Blanck G
JCO Precis Oncol; 2023 Sep; 7():e2300057. PubMed ID: 38085056
[TBL] [Abstract][Full Text] [Related]
2. MYCN induces neuroblastoma in primary neural crest cells.
Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
[TBL] [Abstract][Full Text] [Related]
3. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
Wang M; Zhou C; Cai R; Li Y; Gong L
Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
[TBL] [Abstract][Full Text] [Related]
4. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
5. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe.
Joos S; Scherthan H; Speicher MR; Schlegel J; Cremer T; Lichter P
Hum Genet; 1993 Feb; 90(6):584-9. PubMed ID: 8383093
[TBL] [Abstract][Full Text] [Related]
6. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
7. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
8. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
10. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
11. Direct Targeting of
Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
[TBL] [Abstract][Full Text] [Related]
12. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
13. MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in
Feriancikova B; Feglarova T; Krskova L; Eckschlager T; Vicha A; Hrabeta J
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806217
[TBL] [Abstract][Full Text] [Related]
14. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
15. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.
Wang T; Liu L; Chen X; Shen Y; Lian G; Shah N; Davidoff AM; Yang J; Wang R
Cell Death Dis; 2018 Feb; 9(2):220. PubMed ID: 29445162
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
[TBL] [Abstract][Full Text] [Related]
18. MYCN protein stability is a better prognostic indicator in neuroblastoma.
Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y
BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898
[TBL] [Abstract][Full Text] [Related]
19. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
20. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
